Ginkgo Bioworks Holdings Q4 EPS $(0.11) Misses $(0.10) Estimate, Sales $34.76M Miss $42.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ginkgo Bioworks Holdings (NYSE:DNA) reported Q4 earnings with a loss of $(0.11) per share, missing the $(0.10) estimate, and sales of $34.76M, missing the $42.50M estimate. This represents a 10% increase in losses and an 18.22% miss in sales estimates compared to the same period last year, alongside a 64.64% decrease in sales from $98.28M.
February 29, 2024 | 10:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ginkgo Bioworks Holdings reported a larger than expected Q4 loss and a significant miss in sales estimates, indicating potential challenges in its operational performance.
The reported earnings miss and significant decrease in sales year-over-year suggest operational challenges that could negatively impact investor sentiment and stock price in the short term. The magnitude of the miss in both earnings per share and sales estimates, along with the substantial year-over-year decrease in sales, are critical factors likely to influence the stock's performance negatively.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100